PharmAus19 Floorplan Mural Hall v3-01.png

Exhibitors

Novartis.png

1 - Novartis

Novartis’ display highlights how transformative and innovative medicines effect the patient.

The stand will showcase Novartis’ expertise in the fields of ophthalmology and oncology. It will highlight the patient’s experience by encouraging visitors to use glasses that simulate different eye diseases. A video will be played showcasing Novartis’ offering in the space of ophthalmology.

To highlight the work in the oncology space, Novartis is displaying a real life CAR-T cell holder. This will give visitors insight into how CAR-T therapy and technology works.

Janssen.png

2 - Janssen

The Janssen display showcases the Multiple Myeloma Treatment Shared Decision-Making research project being undertaken by Myeloma Australia supported by Community and Patient Preference Research, Celgene and Janssen Australia.  The research has been designed to allow patients to identify what is important to them when it comes to treatments before going into a consultation with their healthcare professional. This is done via the capture of discrete choice experience of hypothetical treatment scenarios via an App. The preferences identified are then shared, and those findings help form part of the discussion between patient and HCP. The display will allow Parliamentarians to experience the survey via an Ipad.

Abbvie.png

3 - AbbVie

Our Science Impacts Lives

Clinical research is a key component of developing new medicines. AbbVie scientists are leveraging latest technologies and scientific advances to discover and develop new medicines and AbbVie considers Australia a first pass destination for conducting clinical trials. AbbVie are currently testing 23 compounds in 140 active clinical trials with 1300 Australian patients participating in those studies. They are showcasing our clinical trial footprint and will have key personnel from our clinical trials team on hand.  AbbVie will be joined by Blood Cancer Taskforce member and patient advocate Deborah Sims who is passionate about Australia’s participation in clinical trials.

Vifor Pharma.png

4 - Vifor Pharma

Vifor Pharma specialises in innovative and patient-focused treatments for chronic kidney disease and iron deficiency, treating over half a million Australian patients annually.

At the heart of our innovation lies nanomedicines, which are revolutionising the way in which many diseases and conditions can be treated - from cancer and infectious disease, to pain and anaemia. As a manufacturer of nanomedicines, Vifor Pharma understand any minor change in the manufacturing process can alter the therapeutic profile, including the efficacy and safety of a medicine. As part of their commitment to patients, Vifor Pharma will introduce a unique and engaging way to experience the difference that can arise from even a subtle change in manufacturing, leading to differences between a nanomedicine and its follow-on product, a nanosimilar.

Roche.png

5 - Roche

Healthcare is evolving as we learn more about the causes of disease and how medicines work in different patients. Advanced diagnostics (including genomics), data at scale and new treatments are all enabling a more personalised approach to healthcare. As a leader in medicines, diagnostics and healthcare data, Roche’s stand will bring this approach to life with a video outlining what these transformational really mean. Roche representatives will demonstrate how software tools are translating genomics research and clinical trials into personalised treatment plans – and how this is changing the treatment options available to Australian patients.

Eli Lilly.png

6 - Eli Lilly & Headache Australia

A Hidden Epidemic

Migraine is more common than asthma, diabetes and epilepsy combined. It’s the second leading cause of disability globally. 71% per cent of migraine sufferers are women and 86% are of working age. Despite its devastating reach and impact, migraine has been dismissed as "just a headache”. This has lead to an under-diagnosis, under-treatment and poor management of migraine. Consequently, migraine costs have grown to an estimated $35.7 billion each year. Migraine can be managed. Try our virtual migraine experience and speak with Headache Australia and Eli Lilly. Together we can tackle the barriers to effective care.

Merck.png

7 Merck & Genea Bio Med

Merck’s assisted reproductive technologies (ART) have helped bring >  2.7 million babies into the world. Merck will showcase the work of our global partnership with the Australian company, Genea Biomedx, which includes an innovative time-lapse incubator called Geri® that provides stable culture conditions in an optimal environment for embryo growth.

Visitors will see Geri® and video footage of growing embryos.  This technology is being used to save the Northern White Rhino from extinction. Our display will include information on a BioRescue partnership with the Leibniz Institute for Zoo & Wildlife Research which recently announced that two viable Northern White Rhino embryos have been created through ART.

AMGEN.png

8 - Amgen

Visit the Amgen stand to learn more about the Amgen Foundation’s mission to inspire the scientists of tomorrow and our new partnership with Teach for Australia.

This is an opportunity to engage with representatives from Teach for Australia and hear about their vision for an Australia where all children, regardless of background, attain an excellent education.

Participate in an interactive session that allows you to search postcodes to find out how your electorate ranks when it comes to educational opportunities.

Learn more about the Amgen Foundation, the main philanthropic arm of Amgen that funds evidence-based education programs at every level, from the local high school to the world’s premier educational institutions including Sydney University and the University of Melbourne.

Boehringer Ingelheim.png

9 - Boehringer Ingelheim

‘Take Diabetes 2 Heart’ – partnering to improve health

Type 2 diabetes is one of the biggest health challenges facing Australia and heart disease is Australia’s leading cause of death. The national ‘Take Diabetes 2 Heart’ campaign, developed by Diabetes Australia and proudly supported by the Boehringer Ingelheim and Lilly Diabetes Alliance, aims to raise awareness of the link between type 2 diabetes and heart disease. The campaign encourages people living with Type 2 diabetes to have a heart-to-heart with their loved ones about their risks and to visit their GP to learn more about managing their heart health. Visit the stand to know your heart risk and steps that you can take to improve your heart health.

Biogen.png

10 - Biogen

With 2.5 billion people affected by neurological disorders globally and many of them going untreated, Biogen recognises that neuroscience has the potential to make a meaningful difference to many peoples’ lives. As pioneers in neuroscience we aspire to have the greatest impact on patients and science in the history of biotechnology. This cannot be done without partnering with the research and patient communities to realise our pipeline of potential medicines. With a reputation built on our Multiple Sclerosis portfolio and the delivery of the first-ever treatment for Spinal Muscular Atrophy, Biogen has the courage to take risks in the research and development of medicines to transform neuroscience and deliver life-changing benefits to society.

Takeda.png

11 - Takeda

Takeda is a global, values-based, research and development driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its research and development efforts on four therapeutic areas: Oncology, Gastroenterology, Rare Diseases and Neuroscience.

Takeda strives to provide personalised, differentiated and innovative patient services that improve patient outcomes and bring a meaningful experience to patients, healthcare systems and Takeda.

Bayer.png

12 - Bayer

NO Second Chances – controlling risk in cardiovascular disease

The Baker Institute’s ‘No Second Chances’ report is the result of a successful partnership between Bayer and The Baker Heart and Diabetes Institute. A team of clinician researchers, epidemiologists and health economists from the Baker Institute utilised an unrestricted educational grant from Bayer to conduct an academic review of the current state of CVD in Australia and recommend solutions to address the unmet need.

Visit the display which highlights the impact of innovation in the management of CVD in Australia, understand the current burden, and hear about the opportunities that exist to improve patient outcomes.

BMS.png

13 - Bristol-Myers Squibb

Developing and improving access to new and effective oncology treatments is extremely important for Australians diagnosed with cancer. Recent advancements in oncology treatment include medicines that have the ability to activate the patient’s own immune system to fight cancer. Bristol-Myers Squibb Australia will bring to life the potential of Immuno-oncology (IO) and highlight how innovative medicines can transform the way we fight cancer. To showcase the latest developments in cancer treatment, augmented reality will be used to assess the current impact of cancer in Australia, demonstrate the IO journey and explain how IO is having a major impact on patients and the broader community.

Gilead.png

14 - Gilead

Gilead will be showcasing the great work that’s been done in Australia in moving towards hepatitis C elimination, and the success of the partnerships between industry, government, academia and advocacy which brought universal access to a hepatitis C cure to all Australians. To continue Australia’s leading position in the progress towards elimination we must continue the focus and investment to reach all hepatitis C patients, so as to remain on track to meet the WHO hepatitis C elimination target and to further reduce the avoidable morbidity and mortality from this chronic viral infection.

Sanofi.png

15 - Sanofi & Amgen

Sanofi and Amgen are supporting the Heart Foundation to put the spotlight on cardiovascular disease.  Come and use the Heart Age Calculator to find out your heart age compared to your actual age and see if you are at risk of a heart attack or stroke.

Learn how your electorate ranks with heart disease indicators with the Heart Foundation Heart Maps.

The Heart Foundation will highlight the work they are doing to drive the conversation about heart disease and there will be an opportunity to hear from a patient about his experience with familial hypercholesterolaemia.

Lung Foundation.png

16 - Lung Foundation Australia

Taking the Voices to Canberra

Lung Foundation Australia will be presenting their Lung Cancer Scorecard, alongside a showreel featuring the personal stories of 12 people living with lung cancer. The aim is to demonstrate the gaps in research funding, early diagnosis, access to treatment and prognosis. The Lung Foundation have called on the Government to commit to policy interventions, including funding for 25 lung cancer specialist nurses. Guests will be provided with copies of the Scorecard and can watch the showreel as part of our exhibitor stand experience. The Lung Foundation aims to ensure guests are more aware of the inequities and are impassioned to support our initiatives.

17 - The Research & Development Taskforce

The Research and Development Taskforce looks forward to sharing insights into actions needed to ensure Australia continues to be a clinical trials destination of choice.

Clinical trials benefit Australia’s patients, our healthcare system and the broader medical research sector.  They provide patients with early access to innovative treatments, generate evidence that drives improvements in clinical practice and ensure our clinicians gain experience in the latest therapeutic options.

Local and international companies have long viewed Australia as a destination of choice for the conduct of clinical trials.  With ~$1B of industry sponsored trials conducted in Australia each year, clinical trials are important to our economy.

MSD.png

18 - MSD

Clinical trials provide Australian patients with access to breakthrough medicines. This display will showcase MSD’s investment in Australia clinical trials and provide guests with the opportunity to engage with an interactive iPad app to identify the type and number of MSD clinical trials being undertaken in each Federal Electorate. Guests will also be able to speak with MSD’s Global Clinical Trial Operations team about opportunities to increase clinical trial investment in Australia and the importance of clinical trials for patients, the community and the Australian economy.

Biointelect, Pfizer, MSD.png

19 - Pfizer, Biointelect & MSD

Tackling the Growing Threat of Antimicrobial Resistance in Australia (AMR)

This joint display highlights the growing threat of AMR. A new AMR Industry Position Paper will be available which summarises the issues and presents a number of recommendations for urgent actions that are required to help slow the threat of AMR.

Representatives will be available to talk through the recommendations and the ways in which the pharmaceutical industry partners with government, academia, clinicians and the general public to ensure that Australia is at the forefront of tackling this global threat.

Biointelect.png

20 - Biointelect

Bringing Science to Market

Biointelect’s display highlights the challenges in developing new medicines. Biointelect has completed more than 170 projects for 70 clients on commercialisation of health technologies. This experience provides them with a unique view of the life science ecosystem and how to improve research translation and commercialisation in Australia.  Biointelect will introduce case studies of successful collaborations and share ideas on how to avoid the “valley of death” so that patients get access to the medicines that matter.

Prospection.png

21 - Prospection

Real World Data improving outcomes through understanding the Patient Journey

Meet the Prospection team to discuss the Kirby Institute research collaboration.  Understand how analysing real world health data helps visualise the Hepatitis C (HCV) patient journey.  Mapping the epidemiology of HCV, highlighted the population health impact of the disease. Mapping the patient journey highlights current treatment barriers and identifies opportunities for improving treatment access, leading to better patient outcomes and impacts to disease prevalence.  Health Technology and health data is a growing Australian industry, employing our best and brightest STEM graduates to help researchers, academics and industry meet patient needs.

Pfizer.png

22 - Pfizer

Pfizer Melbourne forms an important part of the Pfizer Global Supply network. Pfizer Melbourne's manufacturing focuses on critical oncology and related medicines for the Australian market and over 60 export markets globally. Over 90% of the medicines manufactured at Pfizer Melbourne are exported, providing patients all around the world with life-saving medicines.

Pfizer Melbourne manufactures liposomal, nanoparticle, sterile injectable medicines using the highest standards ensuring that our patients are supplied with high quality medicines.